Shares of Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, edged up 3% to 212.00 kronor today, after it posted financial results for the second quarter of 2023.
Total revenue increased 26%, (+16% at constant exchange rates [CER]), to 4,872 million kronor ($476.2 million).
Adjusted earnings before interest, taxes and amortization (EBITA) margin expanded by 1 percentage point to 26% excluding transaction costs and other items affecting comparability (IAC). EBITA at 1,009 million kronor (944), a margin of 21%. EBIT was 413 million kronor (down 2.4%), adjusted EBIT was 649 million kronor (up 48.5%). Earnings per share (EPS) before dilution were 0.75 kronor (versus 0.87), EPS adjusted before dilution was 1.48 kronor (+62.6%).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze